nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Pancreatitis—Prednisolone—psoriatic arthritis	0.00522	0.00522	CcSEcCtD
Doxylamine—Sweating increased—Prednisolone—psoriatic arthritis	0.00519	0.00519	CcSEcCtD
Doxylamine—Breast disorder—Methylprednisolone—psoriatic arthritis	0.00511	0.00511	CcSEcCtD
Doxylamine—Affect lability—Dexamethasone—psoriatic arthritis	0.00506	0.00506	CcSEcCtD
Doxylamine—Affect lability—Betamethasone—psoriatic arthritis	0.00506	0.00506	CcSEcCtD
Doxylamine—Irritability—Dexamethasone—psoriatic arthritis	0.00491	0.00491	CcSEcCtD
Doxylamine—Irritability—Betamethasone—psoriatic arthritis	0.00491	0.00491	CcSEcCtD
Doxylamine—Mood swings—Betamethasone—psoriatic arthritis	0.00487	0.00487	CcSEcCtD
Doxylamine—Mood swings—Dexamethasone—psoriatic arthritis	0.00487	0.00487	CcSEcCtD
Doxylamine—Bronchospasm—Methylprednisolone—psoriatic arthritis	0.0048	0.0048	CcSEcCtD
Doxylamine—Pancreatitis—Triamcinolone—psoriatic arthritis	0.0048	0.0048	CcSEcCtD
Doxylamine—Pancreatitis—Methylprednisolone—psoriatic arthritis	0.00479	0.00479	CcSEcCtD
Doxylamine—Sweating increased—Triamcinolone—psoriatic arthritis	0.00477	0.00477	CcSEcCtD
Doxylamine—Sweating increased—Methylprednisolone—psoriatic arthritis	0.00476	0.00476	CcSEcCtD
Doxylamine—Affect lability—Prednisone—psoriatic arthritis	0.00441	0.00441	CcSEcCtD
Doxylamine—Bradycardia—Prednisolone—psoriatic arthritis	0.00434	0.00434	CcSEcCtD
Doxylamine—Sweating increased—Betamethasone—psoriatic arthritis	0.00433	0.00433	CcSEcCtD
Doxylamine—Sweating increased—Dexamethasone—psoriatic arthritis	0.00433	0.00433	CcSEcCtD
Doxylamine—Irritability—Prednisone—psoriatic arthritis	0.00427	0.00427	CcSEcCtD
Doxylamine—Polyuria—Methotrexate—psoriatic arthritis	0.00426	0.00426	CcSEcCtD
Doxylamine—Mood swings—Prednisone—psoriatic arthritis	0.00424	0.00424	CcSEcCtD
Doxylamine—Sweating—Methylprednisolone—psoriatic arthritis	0.00418	0.00418	CcSEcCtD
Doxylamine—Bradycardia—Triamcinolone—psoriatic arthritis	0.00399	0.00399	CcSEcCtD
Doxylamine—Bradycardia—Methylprednisolone—psoriatic arthritis	0.00398	0.00398	CcSEcCtD
Doxylamine—Hallucination—Methylprednisolone—psoriatic arthritis	0.00389	0.00389	CcSEcCtD
Doxylamine—Pancreatitis—Prednisone—psoriatic arthritis	0.00379	0.00379	CcSEcCtD
Doxylamine—Sweating increased—Prednisone—psoriatic arthritis	0.00377	0.00377	CcSEcCtD
Doxylamine—Erythema—Prednisolone—psoriatic arthritis	0.00371	0.00371	CcSEcCtD
Doxylamine—Eye disorder—Methylprednisolone—psoriatic arthritis	0.00365	0.00365	CcSEcCtD
Doxylamine—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.00363	0.00363	CcSEcCtD
Doxylamine—Bradycardia—Dexamethasone—psoriatic arthritis	0.00362	0.00362	CcSEcCtD
Doxylamine—Bradycardia—Betamethasone—psoriatic arthritis	0.00362	0.00362	CcSEcCtD
Doxylamine—Irritability—Methotrexate—psoriatic arthritis	0.00357	0.00357	CcSEcCtD
Doxylamine—Mood swings—Methotrexate—psoriatic arthritis	0.00354	0.00354	CcSEcCtD
Doxylamine—Hallucination—Dexamethasone—psoriatic arthritis	0.00354	0.00354	CcSEcCtD
Doxylamine—Hallucination—Betamethasone—psoriatic arthritis	0.00354	0.00354	CcSEcCtD
Doxylamine—Immune system disorder—Methylprednisolone—psoriatic arthritis	0.00353	0.00353	CcSEcCtD
Doxylamine—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00352	0.00352	CcSEcCtD
Doxylamine—Ill-defined disorder—Prednisolone—psoriatic arthritis	0.00344	0.00344	CcSEcCtD
Doxylamine—Depression—Prednisone—psoriatic arthritis	0.00344	0.00344	CcSEcCtD
Doxylamine—Erythema—Triamcinolone—psoriatic arthritis	0.00341	0.00341	CcSEcCtD
Doxylamine—Erythema—Methylprednisolone—psoriatic arthritis	0.0034	0.0034	CcSEcCtD
Doxylamine—Angioedema—Prednisolone—psoriatic arthritis	0.00339	0.00339	CcSEcCtD
Doxylamine—Breast disorder—Methotrexate—psoriatic arthritis	0.00338	0.00338	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Methotrexate—psoriatic arthritis	0.00337	0.00337	CcSEcCtD
Doxylamine—Malaise—Prednisolone—psoriatic arthritis	0.00334	0.00334	CcSEcCtD
Doxylamine—Vertigo—Prednisolone—psoriatic arthritis	0.00333	0.00333	CcSEcCtD
Doxylamine—Eye disorder—Dexamethasone—psoriatic arthritis	0.00332	0.00332	CcSEcCtD
Doxylamine—Eye disorder—Betamethasone—psoriatic arthritis	0.00332	0.00332	CcSEcCtD
Doxylamine—Convulsion—Prednisolone—psoriatic arthritis	0.00321	0.00321	CcSEcCtD
Doxylamine—Pancreatitis—Methotrexate—psoriatic arthritis	0.00317	0.00317	CcSEcCtD
Doxylamine—Ill-defined disorder—Triamcinolone—psoriatic arthritis	0.00316	0.00316	CcSEcCtD
Doxylamine—Ill-defined disorder—Methylprednisolone—psoriatic arthritis	0.00316	0.00316	CcSEcCtD
Doxylamine—Bradycardia—Prednisone—psoriatic arthritis	0.00315	0.00315	CcSEcCtD
Doxylamine—Discomfort—Prednisolone—psoriatic arthritis	0.00312	0.00312	CcSEcCtD
Doxylamine—Angioedema—Triamcinolone—psoriatic arthritis	0.00312	0.00312	CcSEcCtD
Doxylamine—Angioedema—Methylprednisolone—psoriatic arthritis	0.00311	0.00311	CcSEcCtD
Doxylamine—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.0031	0.0031	CcSEcCtD
Doxylamine—Erythema—Dexamethasone—psoriatic arthritis	0.00309	0.00309	CcSEcCtD
Doxylamine—Erythema—Betamethasone—psoriatic arthritis	0.00309	0.00309	CcSEcCtD
Doxylamine—Hallucination—Prednisone—psoriatic arthritis	0.00308	0.00308	CcSEcCtD
Doxylamine—Malaise—Triamcinolone—psoriatic arthritis	0.00308	0.00308	CcSEcCtD
Doxylamine—Pancytopenia—Methotrexate—psoriatic arthritis	0.00307	0.00307	CcSEcCtD
Doxylamine—Malaise—Methylprednisolone—psoriatic arthritis	0.00307	0.00307	CcSEcCtD
Doxylamine—Vertigo—Triamcinolone—psoriatic arthritis	0.00306	0.00306	CcSEcCtD
Doxylamine—Vertigo—Methylprednisolone—psoriatic arthritis	0.00306	0.00306	CcSEcCtD
Doxylamine—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00303	0.00303	CcSEcCtD
Doxylamine—Convulsion—Triamcinolone—psoriatic arthritis	0.00296	0.00296	CcSEcCtD
Doxylamine—Tachycardia—Prednisolone—psoriatic arthritis	0.00295	0.00295	CcSEcCtD
Doxylamine—Convulsion—Methylprednisolone—psoriatic arthritis	0.00295	0.00295	CcSEcCtD
Doxylamine—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.00293	0.00293	CcSEcCtD
Doxylamine—Eye disorder—Prednisone—psoriatic arthritis	0.00289	0.00289	CcSEcCtD
Doxylamine—Anxiety—Methylprednisolone—psoriatic arthritis	0.00289	0.00289	CcSEcCtD
Doxylamine—Drowsiness—Methotrexate—psoriatic arthritis	0.00288	0.00288	CcSEcCtD
Doxylamine—Depression—Methotrexate—psoriatic arthritis	0.00287	0.00287	CcSEcCtD
Doxylamine—Flushing—Prednisone—psoriatic arthritis	0.00287	0.00287	CcSEcCtD
Doxylamine—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.00287	0.00287	CcSEcCtD
Doxylamine—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.00287	0.00287	CcSEcCtD
Doxylamine—Discomfort—Triamcinolone—psoriatic arthritis	0.00287	0.00287	CcSEcCtD
Doxylamine—Discomfort—Methylprednisolone—psoriatic arthritis	0.00286	0.00286	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.00286	0.00286	CcSEcCtD
Doxylamine—Dry mouth—Triamcinolone—psoriatic arthritis	0.00284	0.00284	CcSEcCtD
Doxylamine—Angioedema—Betamethasone—psoriatic arthritis	0.00283	0.00283	CcSEcCtD
Doxylamine—Angioedema—Dexamethasone—psoriatic arthritis	0.00283	0.00283	CcSEcCtD
Doxylamine—Confusional state—Methylprednisolone—psoriatic arthritis	0.0028	0.0028	CcSEcCtD
Doxylamine—Immune system disorder—Prednisone—psoriatic arthritis	0.0028	0.0028	CcSEcCtD
Doxylamine—Malaise—Dexamethasone—psoriatic arthritis	0.00279	0.00279	CcSEcCtD
Doxylamine—Malaise—Betamethasone—psoriatic arthritis	0.00279	0.00279	CcSEcCtD
Doxylamine—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.00278	0.00278	CcSEcCtD
Doxylamine—Vertigo—Betamethasone—psoriatic arthritis	0.00278	0.00278	CcSEcCtD
Doxylamine—Vertigo—Dexamethasone—psoriatic arthritis	0.00278	0.00278	CcSEcCtD
Doxylamine—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.00278	0.00278	CcSEcCtD
Doxylamine—Sweating—Methotrexate—psoriatic arthritis	0.00276	0.00276	CcSEcCtD
Doxylamine—Insomnia—Prednisolone—psoriatic arthritis	0.00274	0.00274	CcSEcCtD
Doxylamine—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00272	0.00272	CcSEcCtD
Doxylamine—Tachycardia—Triamcinolone—psoriatic arthritis	0.00272	0.00272	CcSEcCtD
Doxylamine—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00271	0.00271	CcSEcCtD
Doxylamine—Erythema—Prednisone—psoriatic arthritis	0.0027	0.0027	CcSEcCtD
Doxylamine—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00269	0.00269	CcSEcCtD
Doxylamine—Agranulocytosis—Methotrexate—psoriatic arthritis	0.00269	0.00269	CcSEcCtD
Doxylamine—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00269	0.00269	CcSEcCtD
Doxylamine—Convulsion—Dexamethasone—psoriatic arthritis	0.00268	0.00268	CcSEcCtD
Doxylamine—Convulsion—Betamethasone—psoriatic arthritis	0.00268	0.00268	CcSEcCtD
Doxylamine—Anxiety—Dexamethasone—psoriatic arthritis	0.00263	0.00263	CcSEcCtD
Doxylamine—Anxiety—Betamethasone—psoriatic arthritis	0.00263	0.00263	CcSEcCtD
Doxylamine—Discomfort—Betamethasone—psoriatic arthritis	0.0026	0.0026	CcSEcCtD
Doxylamine—Discomfort—Dexamethasone—psoriatic arthritis	0.0026	0.0026	CcSEcCtD
Doxylamine—Hypotension—Methylprednisolone—psoriatic arthritis	0.0026	0.0026	CcSEcCtD
Doxylamine—Hepatitis—Methotrexate—psoriatic arthritis	0.00259	0.00259	CcSEcCtD
Doxylamine—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.00256	0.00256	CcSEcCtD
Doxylamine—Urethral disorder—Methotrexate—psoriatic arthritis	0.00254	0.00254	CcSEcCtD
Doxylamine—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Doxylamine—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Doxylamine—Insomnia—Triamcinolone—psoriatic arthritis	0.00252	0.00252	CcSEcCtD
Doxylamine—Insomnia—Methylprednisolone—psoriatic arthritis	0.00251	0.00251	CcSEcCtD
Doxylamine—Ill-defined disorder—Prednisone—psoriatic arthritis	0.0025	0.0025	CcSEcCtD
Doxylamine—Feeling abnormal—Prednisolone—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Doxylamine—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00248	0.00248	CcSEcCtD
Doxylamine—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00248	0.00248	CcSEcCtD
Doxylamine—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00248	0.00248	CcSEcCtD
Doxylamine—Agitation—Prednisone—psoriatic arthritis	0.00248	0.00248	CcSEcCtD
Doxylamine—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Doxylamine—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Doxylamine—Tachycardia—Dexamethasone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Doxylamine—Tachycardia—Betamethasone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Doxylamine—Angioedema—Prednisone—psoriatic arthritis	0.00246	0.00246	CcSEcCtD
Doxylamine—Erythema multiforme—Methotrexate—psoriatic arthritis	0.00245	0.00245	CcSEcCtD
Doxylamine—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00244	0.00244	CcSEcCtD
Doxylamine—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00244	0.00244	CcSEcCtD
Doxylamine—Malaise—Prednisone—psoriatic arthritis	0.00243	0.00243	CcSEcCtD
Doxylamine—Vertigo—Prednisone—psoriatic arthritis	0.00242	0.00242	CcSEcCtD
Doxylamine—Eye disorder—Methotrexate—psoriatic arthritis	0.00242	0.00242	CcSEcCtD
Doxylamine—Anorexia—Betamethasone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Doxylamine—Anorexia—Dexamethasone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Doxylamine—Urticaria—Prednisolone—psoriatic arthritis	0.0024	0.0024	CcSEcCtD
Doxylamine—Cardiac disorder—Methotrexate—psoriatic arthritis	0.0024	0.0024	CcSEcCtD
Doxylamine—Fatigue—Triamcinolone—psoriatic arthritis	0.0024	0.0024	CcSEcCtD
Doxylamine—Fatigue—Methylprednisolone—psoriatic arthritis	0.00239	0.00239	CcSEcCtD
Doxylamine—Hypotension—Betamethasone—psoriatic arthritis	0.00236	0.00236	CcSEcCtD
Doxylamine—Hypotension—Dexamethasone—psoriatic arthritis	0.00236	0.00236	CcSEcCtD
Doxylamine—Immune system disorder—Methotrexate—psoriatic arthritis	0.00234	0.00234	CcSEcCtD
Doxylamine—Convulsion—Prednisone—psoriatic arthritis	0.00234	0.00234	CcSEcCtD
Doxylamine—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00233	0.00233	CcSEcCtD
Doxylamine—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.00229	0.00229	CcSEcCtD
Doxylamine—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.00229	0.00229	CcSEcCtD
Doxylamine—Anxiety—Prednisone—psoriatic arthritis	0.00229	0.00229	CcSEcCtD
Doxylamine—Insomnia—Dexamethasone—psoriatic arthritis	0.00228	0.00228	CcSEcCtD
Doxylamine—Insomnia—Betamethasone—psoriatic arthritis	0.00228	0.00228	CcSEcCtD
Doxylamine—Discomfort—Prednisone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Doxylamine—Erythema—Methotrexate—psoriatic arthritis	0.00225	0.00225	CcSEcCtD
Doxylamine—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Doxylamine—Urticaria—Triamcinolone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Doxylamine—Urticaria—Methylprednisolone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Doxylamine—Anaphylactic shock—Prednisone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Doxylamine—Decreased appetite—Dexamethasone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Doxylamine—Decreased appetite—Betamethasone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
Doxylamine—Fatigue—Dexamethasone—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
Doxylamine—Fatigue—Betamethasone—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
Doxylamine—Nervous system disorder—Prednisone—psoriatic arthritis	0.00216	0.00216	CcSEcCtD
Doxylamine—Tachycardia—Prednisone—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Doxylamine—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00213	0.00213	CcSEcCtD
Doxylamine—Anorexia—Prednisone—psoriatic arthritis	0.0021	0.0021	CcSEcCtD
Doxylamine—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Doxylamine—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Doxylamine—Feeling abnormal—Betamethasone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Doxylamine—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00205	0.00205	CcSEcCtD
Doxylamine—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00205	0.00205	CcSEcCtD
Doxylamine—Malaise—Methotrexate—psoriatic arthritis	0.00203	0.00203	CcSEcCtD
Doxylamine—Vertigo—Methotrexate—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Doxylamine—Leukopenia—Methotrexate—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Doxylamine—Urticaria—Betamethasone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Doxylamine—Urticaria—Dexamethasone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Doxylamine—Dizziness—Prednisolone—psoriatic arthritis	0.002	0.002	CcSEcCtD
Doxylamine—Asthenia—Triamcinolone—psoriatic arthritis	0.002	0.002	CcSEcCtD
Doxylamine—Asthenia—Methylprednisolone—psoriatic arthritis	0.00199	0.00199	CcSEcCtD
Doxylamine—Insomnia—Prednisone—psoriatic arthritis	0.00199	0.00199	CcSEcCtD
Doxylamine—Pruritus—Triamcinolone—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Doxylamine—Pruritus—Methylprednisolone—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Doxylamine—Convulsion—Methotrexate—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Doxylamine—Decreased appetite—Prednisone—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Doxylamine—Rash—Prednisolone—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Doxylamine—Dermatitis—Prednisolone—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Doxylamine—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Doxylamine—Fatigue—Prednisone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Doxylamine—Discomfort—Methotrexate—psoriatic arthritis	0.00189	0.00189	CcSEcCtD
Doxylamine—Constipation—Prednisone—psoriatic arthritis	0.00188	0.00188	CcSEcCtD
Doxylamine—Confusional state—Methotrexate—psoriatic arthritis	0.00185	0.00185	CcSEcCtD
Doxylamine—Dizziness—Triamcinolone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Doxylamine—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Doxylamine—Dizziness—Methylprednisolone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Doxylamine—Feeling abnormal—Prednisone—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Doxylamine—Asthenia—Dexamethasone—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Doxylamine—Asthenia—Betamethasone—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Doxylamine—Nervous system disorder—Methotrexate—psoriatic arthritis	0.0018	0.0018	CcSEcCtD
Doxylamine—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.0018	0.0018	CcSEcCtD
Doxylamine—Nausea—Prednisolone—psoriatic arthritis	0.0018	0.0018	CcSEcCtD
Doxylamine—Pruritus—Dexamethasone—psoriatic arthritis	0.00179	0.00179	CcSEcCtD
Doxylamine—Pruritus—Betamethasone—psoriatic arthritis	0.00179	0.00179	CcSEcCtD
Doxylamine—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.00178	0.00178	CcSEcCtD
Doxylamine—Vomiting—Triamcinolone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Doxylamine—Vomiting—Methylprednisolone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Doxylamine—Rash—Triamcinolone—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Doxylamine—Dermatitis—Triamcinolone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Doxylamine—Anorexia—Methotrexate—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Doxylamine—Rash—Methylprednisolone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Doxylamine—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Doxylamine—Urticaria—Prednisone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Doxylamine—Diarrhoea—Betamethasone—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Doxylamine—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Doxylamine—Hypotension—Methotrexate—psoriatic arthritis	0.00172	0.00172	CcSEcCtD
Doxylamine—Dizziness—Betamethasone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Doxylamine—Dizziness—Dexamethasone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Doxylamine—Insomnia—Methotrexate—psoriatic arthritis	0.00166	0.00166	CcSEcCtD
Doxylamine—Nausea—Triamcinolone—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Doxylamine—Nausea—Methylprednisolone—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Doxylamine—Dyspnoea—Methotrexate—psoriatic arthritis	0.00164	0.00164	CcSEcCtD
Doxylamine—Somnolence—Methotrexate—psoriatic arthritis	0.00163	0.00163	CcSEcCtD
Doxylamine—Hypersensitivity—Prednisone—psoriatic arthritis	0.00162	0.00162	CcSEcCtD
Doxylamine—Vomiting—Dexamethasone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Doxylamine—Vomiting—Betamethasone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Doxylamine—Decreased appetite—Methotrexate—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Doxylamine—Rash—Dexamethasone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Doxylamine—Rash—Betamethasone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Doxylamine—Dermatitis—Betamethasone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Doxylamine—Dermatitis—Dexamethasone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Doxylamine—Fatigue—Methotrexate—psoriatic arthritis	0.00158	0.00158	CcSEcCtD
Doxylamine—Asthenia—Prednisone—psoriatic arthritis	0.00158	0.00158	CcSEcCtD
Doxylamine—Pruritus—Prednisone—psoriatic arthritis	0.00156	0.00156	CcSEcCtD
Doxylamine—Feeling abnormal—Methotrexate—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Doxylamine—Diarrhoea—Prednisone—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Doxylamine—Nausea—Dexamethasone—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Doxylamine—Nausea—Betamethasone—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Doxylamine—Urticaria—Methotrexate—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Doxylamine—Dizziness—Prednisone—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Doxylamine—Vomiting—Prednisone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Doxylamine—Rash—Prednisone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Doxylamine—Dermatitis—Prednisone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Doxylamine—Hypersensitivity—Methotrexate—psoriatic arthritis	0.00135	0.00135	CcSEcCtD
Doxylamine—Asthenia—Methotrexate—psoriatic arthritis	0.00132	0.00132	CcSEcCtD
Doxylamine—Nausea—Prednisone—psoriatic arthritis	0.00131	0.00131	CcSEcCtD
Doxylamine—Pruritus—Methotrexate—psoriatic arthritis	0.0013	0.0013	CcSEcCtD
Doxylamine—Diarrhoea—Methotrexate—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Doxylamine—Dizziness—Methotrexate—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Doxylamine—Vomiting—Methotrexate—psoriatic arthritis	0.00117	0.00117	CcSEcCtD
Doxylamine—Rash—Methotrexate—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Doxylamine—Dermatitis—Methotrexate—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Doxylamine—Nausea—Methotrexate—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
